Barr Announces Agreements on Nasacort(R) AQ, Allegra(R) D-12 and Allegra(R) Patent ...( - Settlement and License Agreement fo...),Health

- Settlement and License Agreement for Generic Versions of Nasacort(R) AQ

- Settlement and License Agreement with Aventis and Albany Molecular Research, Inc. for Generic Versions of Allegra(R) D-12

- Settlement Agreement with Aventis and Albany Molecular Research, Inc. Related to Generic Versions of Allegra(R) Tablets

MONTVALE, N.J., Nov. 19 /PRNewswire-FirstCall/ --Barr Pharmaceuticals, Inc. (NYSE: BRL) today announced that its subsidiary, Barr Laboratories, Inc. has entered into separate settlement agreements related to ongoing patent challenges for Nasacort(R) AQ (triamcinolone acetonide) nasal spray, Allegra(R) D-12 Hour (fexofenadine hydrochloride 60mg and pseudoephedrine hydrochloride 120mg) extended-release tablets, and Allegra(R) (fexofenadine) 30mg, 60mg and 180mg tablets. As part of the settlements, the parties have agreed to dismiss the underlying U.S. litigation related to the three patent challenge cases.

"We are very pleased to have reached these three separate settlements, bringing to a close the outstanding patent challenges in a manner that results in the date certain launch of a generic version of Nasacort(R) AQ years prior to the expiration of the applicable patents, and the launch of a generic version of Allegra(R) D-12 in November of 2009," said Bruce L. Downey, Barr's Chairman and CEO. "The agreement related to Allegra(R) resolves any ongoing uncertainty about the possible impact of ongoing litigation for Barr and Teva related to the launch of generic versions of Allegra(R) 30mg, 60mg and 180mg tablets in September 2005. We believe that these agreements represent a pro-consumer resolution to this ongoing litigation."

The individual agreements are subject to review by the Federal Trade Commission (FTC) and state Attorneys General under
'/>"/>